Universal Health Services, Inc. research snapshot
UHS AI stock analysis currently reads Universal Health Services as a profitable acute care and behavioral health operator with strong FY2025 earnings, Q1 2026 revenue growth, and low headline valuation multiples, offset by reimbursement exposure, labor cost risk, behavioral health scrutiny, debt, and weak longer-term price momentum. At the July 8, 2026 data cutoff, UHS traded near $152.48 with a verified market capitalization near $9.23 billion. The UHS AI stock forecast uses scenario ranges rather than a fixed price prediction because admissions, payer mix, Medicaid programs, wage inflation, regulatory risk, capital spending, and valuation multiples can change quickly.
Current price
$152.48
Market cap
$9.23 billion verified market cap
AI score
69 / 100
Rating
Profitable hospital and behavioral health operator with policy, labor, leverage, and momentum risk
Trend status
Rebounding from recent lows but still below the 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | UHS owns and operates acute care hospitals, behavioral health facilities, outpatient sites, and related healthcare services that serve recurring patient needs. | High |
| Moat | The moat comes from local facility networks, licenses, physician relationships, payer contracts, behavioral health capacity, and operating know-how, but it is limited by regulation and payer bargaining power. | Medium |
| Management | CEO Marc Miller has been CEO since January 2021 and has spent decades inside UHS operations. The current test is capital discipline across repurchases, capacity investment, debt, and Talkspace integration. | Medium-high |
| Financial trend | FY2025 revenue increased 9.7% to $17.365 billion and net income attributable to UHS rose to $1.489 billion. Q1 2026 revenue increased 9.6% to $4.495 billion. | High |
| Valuation | At $152.48, audited tool math shows about 6.72x TTM EPS, 0.52x sales, 10.11x free cash flow per share, and a 0.52% dividend yield. | High |
| Technical trend | The stock has bounced from recent lows but remains below key moving averages near the mid-$150s and the high-$190s, so trend confirmation is incomplete. | Medium |
| Risk level | Main risks include labor cost inflation, Medicaid and Medicare reimbursement, payer mix, behavioral health regulation, legal exposure, leverage, acquisitions, and capital spending needs. | Medium-high |
| AI confidence | Descriptive confidence is high because company releases, Macrotrends, StockAnalysis, and proxy data agree on core facts. Return confidence is lower because policy and sentiment can reprice hospital operators fast. | High data confidence |
| Investment certainty | UHS has value characteristics, but a stronger setup needs stable volumes, controlled labor costs, reimbursement clarity, debt discipline, and a sustained move above the 200-day average. | Medium |
UHS AI stock forecast
The UHS AI stock forecast is scenario-based because hospital earnings depend on admissions, revenue per adjusted admission, behavioral health utilization, wage costs, payer policy, debt, and market multiples. Using the $152.48 price reference, TTM EPS near $22.69, and an audited three-year model, the mechanical outcomes are about $264.50 in a bullish case, $183.90 in a base case, and $97.30 in a bearish case before dividends.
$245 to $270 before dividends
More likely if acute care and behavioral health revenue continue growing, labor pressure stays controlled, adjusted EBITDA margin holds near the mid-teens, debt leverage stays manageable, and the market applies a high-single-digit earnings multiple to higher EPS.
$175 to $190 before dividends
More likely if EPS compounds near a mid-single-digit rate, UHS meets 2026 operating expectations, the Talkspace acquisition closes without balance-sheet strain, and investors value the company near a 7x earnings multiple.
$90 to $105 before dividends
More likely if admissions soften, reimbursement or Medicaid supplemental payments disappoint, labor inflation returns, behavioral health scrutiny rises, debt increases, or the market compresses UHS toward a low earnings multiple.
UHS AI technical analysis
UHS AI technical analysis is cautious as of the July 8, 2026 data cutoff. StockAnalysis showed UHS near $152.48 intraday with market cap near $9.23 billion, while technical sources placed the 50-day moving average around $156 to $157 and the 200-day moving average around $196. MarketWatch reported a July 7, 2026 close of $161.26, still far below the November 26, 2025 52-week high near $246.33.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $152.48 | StockAnalysis intraday price reference from July 8, 2026 at 11:04 AM EDT, used for market-cap and valuation math. |
| Immediate support | $141 to $145 | Recent trading references and moving-average services show the stock rebounding from the low-$140s area. |
| Deeper support | $134 to $140 | A sustained break below this zone would weaken the rebound setup and signal that the value thesis is losing price support. |
| Near resistance | $156 to $163 | This brackets the 50-day moving average area and the July 7 close near $161.26. |
| Major resistance | $190 to $200 | The 200-day moving average is near the high-$190s on StockAnalysis, Barchart, and TipRanks style technical feeds. |
| Moving averages | 50-day near $156 to $157, 200-day near $196 | Price below both averages supports a rebound watchlist rather than a confirmed long-term uptrend. |
| Momentum | RSI roughly neutral to positive | StockAnalysis and TipRanks style readings put RSI in the low-to-mid 60s, which supports short-term strength but not a clean trend reversal by itself. |
| Volume | 20-day volume near 0.9 million to 1.1 million shares | Volume confirmation matters around the July 27, 2026 confirmed earnings date and reimbursement or acquisition updates. |
| Volatility | Watch earnings, Medicaid, labor, legal, and behavioral health headlines | Hospital operators can gap when payer mix, Medicaid payments, staffing costs, compliance risk, or guidance changes. |
| Invalidation | Close below $140, then below $134 | A sustained break below recent support would challenge the mean-reversion setup and shift attention back to earnings downside risk. |
UHS AI trading strategy
The UHS AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with admissions, revenue per adjusted admission, payer mix, labor cost, behavioral health utilization, debt, and cash flow.
Watch for UHS to reclaim the $156 to $163 area with improving volume, then test the $190 to $200 long-term moving-average zone while Q2 results confirm stable admissions and margins.
A failed move near the 50-day area followed by a close below $140 should reduce trend confidence, especially if earnings commentary points to weaker volumes or higher labor cost.
If UHS holds the low-$140s without a permanent earnings reset, compare the lower price with FY2025 EPS, TTM free cash flow, debt, peer hospital operators, and 2026 guidance.
Do not treat a low P/E as enough if reimbursement assumptions worsen, behavioral health legal risk rises, or capital spending and acquisitions increase leverage.
Track acute care adjusted admissions, behavioral health adjusted patient days, revenue per adjusted admission, wage inflation, supply costs, Medicaid supplemental payments, debt, buybacks, capex, and Talkspace integration.
Position sizing should reflect that UHS can look statistically cheap before policy, legal, labor, or sentiment risk appears in reported EPS.
Investment research summary
Patients, insurers, employers, and government programs pay UHS because communities need hospital beds, emergency care, acute care procedures, outpatient services, and behavioral health capacity. The business converts recurring healthcare demand into facility revenue and cash flow.
The moat is strongest in local hospital networks, licenses, physician relationships, payer contracts, care capacity, operating know-how, and behavioral health footprint. It can narrow if payers gain leverage, regulators tighten rules, or competitors expand outpatient and specialty capacity.
The thesis fails if labor inflation outruns pricing, Medicaid or Medicare reimbursement weakens, behavioral health scrutiny increases, admissions soften, Talkspace integration disappoints, or debt and capex reduce financial flexibility.
Marc Miller has deep UHS operating history and has led the company since 2021. The key management test is balancing repurchases, growth investment, digital behavioral health expansion, debt, and compliance discipline.
Hospital and behavioral health demand benefit from aging demographics, chronic disease, mental health demand, acuity, and care-access needs. The offset is that healthcare affordability keeps government, payer, employer, and patient scrutiny high.
At $152.48, UHS trades at low earnings and sales multiples, which gives the stock a value screen. Margin of safety still depends on whether FY2025 earnings power is durable after labor, payer, policy, legal, and leverage risks are considered.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $152.48 intraday on July 8, 2026 | StockAnalysis UHS statistics | July 8, 2026 |
| Market capitalization | $9.23 billion, verified against 60.54 million shares | StockAnalysis UHS statistics | July 8, 2026 |
| FY2025 revenue | $17.365 billion | UHS FY2025 results release | July 8, 2026 |
| FY2025 net income attributable to UHS | $1.489 billion | UHS FY2025 results release | July 8, 2026 |
| Q1 2026 revenue and net income | $4.495 billion revenue and $348.7 million net income attributable to UHS | UHS Q1 2026 results release | July 8, 2026 |
| Q1 2026 segment same-facility growth | Acute care revenues +8.2%, behavioral health revenues +7.3% | UHS Q1 2026 results release | July 8, 2026 |
| FY2025 cash and debt | $137.8 million cash and $4.753 billion debt at Dec. 31, 2025 | UHS FY2025 balance sheet | July 8, 2026 |
| Q1 2026 debt and operating cash flow | $4.708 billion debt and $401.6 million operating cash flow | UHS Q1 2026 results release | July 8, 2026 |
| Valuation ratios | 6.72x PE, 0.55x sales, 10.70x P/FCF, 0.52% dividend yield | StockAnalysis UHS statistics | July 8, 2026 |
| CEO tenure | Marc D. Miller named CEO in January 2021 and President since 2009 | UHS leadership profile | July 8, 2026 |
This UHS AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of returns. Forecast scenarios are based on available data as of July 8, 2026 and can be wrong if earnings, reimbursement, regulation, labor costs, litigation, debt, market liquidity, or investor sentiment changes.
